Antibody-Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations.
Saved in:
| Title: | Antibody-Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations. |
|---|---|
| Authors: | Sorret L; Drug Product Formulation Development, Lonza AG, Hochbergerstrasse 60G, 4057, Basel, Switzerland., Ninomiya M; Preclinical Development Bioconjugates, Lonza AG, Rottenstrasse 6, 3930, Visp, Switzerland., Hillebrandt N; Drug Product Process Development, Lonza AG, Hochbergerstrasse 60G, 4057, Basel, Switzerland., Schmitt D; Drug Product Formulation Development, Lonza AG, Hochbergerstrasse 60G, 4057, Basel, Switzerland., Chattopadhyay A; Drug Product Process Development, Lonza AG, Hochbergerstrasse 60G, 4057, Basel, Switzerland., McGarvey O; Drug Product Process Development, Lonza AG, Hochbergerstrasse 60G, 4057, Basel, Switzerland. orla.mcgarvey@lonza.com. |
| Source: | AAPS PharmSciTech [AAPS PharmSciTech] 2026 Jun 04; Vol. 27 (5). Date of Electronic Publication: 2026 Jun 04. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 100960111 Publication Model: Electronic Cited Medium: Internet ISSN: 1530-9932 (Electronic) Linking ISSN: 15309932 NLM ISO Abbreviation: AAPS PharmSciTech Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
